Prognostic and predictive value of thymidine labelling index in breast cancer

Breast Cancer Research and Treatment

Volumn 51, Issue 3, 1998, Pages 267-281

  Amadori, D ^a   Silvestrini, Rosella ^b  

^a Ospedale Pierantoni   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer; Cell kinetics; Prognosis; Thymidine labelling index; Tumor progression

Indexed keywords

DNA; STEROID RECEPTOR; THYMIDINE;

BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL FRACTIONATION; CELL KINETICS; FEMALE; HUMAN; LABELING INDEX; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVIEW; TUMOR GROWTH;

EID: 0032411679     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006140629766     Document Type: Review

References (70)

1. Perlman AW: Breast cancer. Influence of growth rate on prognosis and treatment evolution. Cancer 38:1826-1833, 1976
2. Philippe E, Le Gal Y: Growth of p78 recurrent mammary cancers. Cancer 21:461-467, 1968
3. Gershon-Cohen J, Berger SN, Klickstein SH: Roentgenography of breast cancer moderating concept of biologic predeterminism. Cancer 16:961-964, 1963
4. Kusama S, Spradt JS, Donegan WL, Watson FR, Cunningham C: The gross rate of growth of human mammary carcinoma. Cancer 16:594-599, 1972
5. Tubiana M, Malaise EP: Growth rate and cell kinetics in human tumours: some prognostic and therapeutic implications. In: Symington T, Certer RL (eds) Scientific Foundation of Oncology. Heinemann, London, 1976, pp 126-135
6. Mendelsohn ML, Dohan FC, Moore HA: Autoradiographic analysis of cell proliferation in spontaneous breast cancer of C3H mouse. J Natl Cancer Inst 25:476-484, 1960
7. Steel GG: Growth Kinetics of Tumours. Clarendon Press, Oxford, 1977
8. Silvestrini R, Daidone MG, Costa A: Determination of the proliferative fraction in human tumors. In: Studzinski GP (ed) Cell Growth and Apoptosis. A Practical Approach. IRL Oxford University Press, Oxford, 1995, pp 59-77
9. Chavaudra N, Richard JM, Malaise EP: Labelling index of human squamous cell carcinomas. Cell Tissue Kinet 12:145-152, 1979
10. Denekamp J, Kallman RF: In vitro and in vivo labelling of animal tumors with tritiated thymidine. Cell Tissue Kinet 6:217-227, 1973
11. Meyer JS, Bauer WC: In vitro determination of tritiated thymidine labelling index: Evaluation of a method utilizing hyperbaric oxygen and observation of the LI of human mammary carcinoma. Cancer 36:1374-1380, 1975
12. Silvestrini R, Sanfilippo O, Lenaz L: Confronto tra i parametri cinetici in vivo e in vitro del sarcoma 180 solido. Tumori 58:335-339, 1972
13. Sklarew R, Hoffman J, Post J: A rapid in vitro method for measuring cell proliferation in human breast cancer. Cancer 40:2299-2302, 1977
14. 3H-TdR Labeling Index in breast cancer. Cell Prolif 21:437-445, 1991
15. Meyer JS: Cell proliferation in normal human breast ducts, fibroadenomas, and other ductal hyperplasias measured by nuclear labeling with tritiated thymidine. Effects of menstrual phase, age, and oral contraceptive hormones. Human Pathol 8:67-81, 1977
16. Di Martino L, Silvestrini R, Benini E, Faranda A, De Montis B, Murenu G, Ferreli A, Daidone MG: P53, Bcl-2 expression and cell proliferation in benign breast lesions. Int J Oncol 8:1053-1057, 1996
17. Silvestrini R, Daidone MG, Gentili C: Biologic characteristics of breast cancer and their clinical relevance. In: Bulbrook RD, Taylor DJ (eds) Commentaries on Research in Breast Cancer. A.R. Liss Inc, 1981, pp 1-40
18. Silvestrini R, Sanfilippo O, Tedesco G: Kinetics of human mammary carcinomas and their correlation with the cancer and the host characteristics. Cancer 34:1252-1258, 1974
19. Gentili C, Sanfilippo O, Silvestrini R: Cell proliferation in relation to clinical features and relapse in breast cancers. Cancer 48:974-979, 1981
20. 3H-thymidine labelling index. Int J Cancer (Pred Oncol) 74:122-127, 1997
21. Meyer JS, Bauer WC: In vitro determination of tritiated thymidine labeling index. Evaluation of a method utilizing hyperbaric oxygen and observations on TLI of human mammary carcinoma. Cancer 36:1374-1380, 1975
22. Meyer JS, Bauer WC: Tritiated thymidine labeling index of benign and malignant human breast epithelium. J Surg Oncol 8:165-181, 1976
23. Meyer JS, Facher R: Thymidine labeling index of human breast carcinoma. Enhancement of in vitro labeling by 5-fluorouracil and 5-fluoro-2′-deoxyuridine. Cancer 39:2524-2532, 1977
24. Meyer JS, Hixon B: Advanced stage and early relapse of breast carcinomas associated with high thymidine labeling indices. Cancer Res 39:4042-4047, 1979
25. Schiffer LM, Braunschweiger PG, Stragand JJ, Poulakos L: The cell kinetics of human mammary cancers. Cancer 43:1707-1709, 1979
26. 3H-thymidine labeling index, hormone receptors and ploidy in breast cancer from elderly patients. Breast Cancer Res Treat 20:19-24, 1991
27. Silvestrini R, Benini E, Luisi A, Veneroni S, Valentinis B, Daidone MG: Biology of breast cancer in elderly women. Mastology - Breast Disease, Figueira Fo ASS et al (eds), 1995, pp 255-258
28. Meyer JS, Prey MU, Babcock DS, McDivitt RW: Breast carcinoma cell kinetics, morphology, stage, and host characteristics. A thymidine labeling study. Lab Invest 54:41-51, 1986
29. Amadori D, Bonaguri C, Nanni O, Gentilini P, Lundi N, Zoli W, Riccobon A, Vio A, Magni E, Saragoni A: Cell kinetics and hormonal features in relation to pathological stage in breast cancer. Breast Cancer Res Treat 18:19-25, 1991
30. Silvestrini R, Daidone MG, Di Fronzo G: Relationship between proliferative activity and estrogen receptors in breast cancer. Cancer 44:665-670, 1979
31. Bertuzzi A, Daidone MG, Di Fronzo G, Silvestrini R: Relationship among estrogen receptors, proliferative activity and menopausal status in breast cancer. Breast Cancer Res Treat 1:253-262, 1981
32. Silvestrini R, Daidone MG, Bertuzzi A, Di Fronzo G: Relationship between estrogen receptors and cellular proliferation. Recent Results Cancer Res 91:163-168, 1984
33. Silvestrini R, Luisi A, Daidone MG, Di Mauro MG: Effect of menstrual phase on cell proliferation rate of breast cancer. Breast Cancer Res Treat, in press
34. Costa A, Del Bino G, Ventura L, Silvestrini R: Relationship between cell kinetics of primary tumor and lymph node metastases of the same patient. Cell Tissue Kinet 17:302, 1984
35. 3H-thymidine labeling index. Cell Tissue Kinet 23:401-408, 1990
36. Meyer JS, Lee JY: Relationship of S phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness, and duration of survival. Cancer Res 40:1890-1896, 1980
37. Meyer JS, McDivitt RW: Reliability and stability of the thymidine labeling index of breast carcinoma. Lab Invest 54:160-164, 1986
38. Silvestrini R, Valentinis B, Daidone MG, Di Fronzo G, Coradini D, Salvadori B: Biological characterization of primary and metachronous lesions in breast cancer patients. Eur J Cancer 28A:2006-2010, 1992
39. R Silvestrini et al: Quality control for the evaluation of the S-phase fraction by flow cytometry: a multi-centric study. Cytometry (Communications in Clinical Cytometry) 18:11-16, 1994
40. Tubiana M, Pejovic MH, Chavaudra N, Contesso G, Malaise EP: The long term prognostic significance of the thymidine labeling index in breast cancer. Int J Cancer 33:441-445, 1984
41. Meyer JS, Friedman E, McCrote MM, Bauer WC: Prediction of early course of breast carcinoma by thymidine labeling. Cancer 51:1879-1886, 1983
42. Hery M, Gioanni J, Lalanne CM, Namer M, Coudri A: The DNA labeling index: a prognostic factor in node-negative breast cancer. Breast Cancer Res Treat 9:207-212, 1987
43. Meyer JS, Province M: Proliferative index of breast cancer by thymidine labeling index: prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res Treat 12:191-203, 1988
44. Silvestrini R, Daidone MG, Valagussa P, Di Fronzo G, Mezzanotte G, Bonadonna G: Cell kinetics as a prognostic indicator in node-negative breast cancer. Eur J Cancer Clin Oncol 25:1165-1171, 1989
45. Silvestrini R, Daidone MG, Di Fronzo G, Morabito A, Valagussa P, Bonadonna G: Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer. Breast Cancer Res Treat 7:161-169, 1986
46. -: attività proliferativa e caratteristiche clinico-patologiche. Folia Oncol 3:1-13, 1992
47. Tubiana M, Pejovic MH, Koscielny S, Chavaudra N, Malaise E: Growth rate, kinetics of tumor cell proliferation, and long term outcome in human breast cancer. Int J Cancer 44:17-22, 1987
48. Cooke TG, Stanton PD, Winstanley J, Murray GD, Croton R, Holt S, George WD: Long term prognostic significance of thymidine labeling index in primary breast cancer. Eur J Cancer 28:424-426, 1992
49. Silvestrini R, Daidone MG, Gasparini G: Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer 56:1982-1987, 1985
50. Silvestrini R, Daidone MG, Luisi A, Boracchi P, Mezzetti M, Di Fronzo G, Andreola S, Veronesi U: Biologic and clinico-pathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol 13:697-704, 1995
51. Meyer JS, Province M: Proliferative index of breast cancer by thymidine labeling index: prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res Treat 12:191-203, 1988
52. Silvestrini R, Daidone MG, Del Bino G, Mastore M, Di Fronzo G, Boracchi P: Prognostic significance of proliferative activity and ploidy in node-negative breast cancers. Ann Oncol 4:213-219, 1993
53. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U: P53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85:965-970, 1993
54. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Veronesi U: The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86:499-504, 1994
55. Rudas M, Gnant MG, Mittlbock M, Neumayer R, Kummer A, Jakesz R, Reiner G, Reiner A: Thymidine labeling index and Ki-67 growth fraction in breast cancer: comparison and correlation with prognosis. Breast Cancer Res Treat 32:165-175, 1994
56. Silvestrini R, Daidone MG, Benini E, Faranda A, Tomasic G, Boracchi P, Salvadori B, Veronesi U: Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers. Clin Cancer Res 2:2007-2013, 1996
57. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1-15, 1992
58. Silvestrini R, Daidone MG, Valagussa P, Salvadori B, Rovini D, Bonadonna G: Cell kinetics and prognosis in locally advanced breast cancer. Cancer Treat Rep, 70:375-379, 1987
59. Sulkes, A, Livingstone RB, Murphy WK: Tritiated thymidine labeling index and response in human breast cancer. J Natl Cancer Inst 62:513-515, 1979
60. Amadori D, Volpi A, Maltoni R, Nanni O, Amaducci L, Amadori A, Casadei Giunchi D, Vio A, Saragoni A, Silvestrini R: Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective study. Breast Cancer Res Treat 43:7-14, 1997
61. Gardin G, Alama A, Rosso R, Campora E, Repetto L, Pronzato P, Merlini L, Naso C, Camoriano A, Meazza R: Relationship of variations in tumor cell kinetics induced by primary chemotherapy to tumor regression and prognosis in locally advanced breast cancer. Breast Cancer Res Treat 32:311-318, 1994
62. Daidone MG, Silvestrini R, Canova S, Valagussa P: Tumor cell kinetics and course of node-positive breast cancer. Proc ASCO 8:24, 1989
63. Bonadonna G, Valagussa P, Tancini G, Rossi A, Brambilla C, Zambetti M, Bignami P, Di Fronzo G, Silvestrini R: Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer. NCI Monographs 1:45-49, 1986
64. Zambetti M, Bonadonna G, Valagussa P, Daidone MG, Coradini D, Bignami P, Contesso G, Silvestrini R: Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer. NCI Monographs 11:77-83, 1992
65. Daidone MG, Silvestfini R, Valentinis B, Ferrari L, Bartoli C: Changes in cell kinetics induced by primary chemotherapy in breast cancer. Int J Cancer 47:380-383, 1990
66. Paradiso A, Tommasi S, Mangia A, Lorusso V: Tumor proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer. Cancer Res 50:2958-2962, 1990
67. Amadori D, Volpi A, Callea A: Clinical relevance of cell kinetics in breast cancer. Ann NY Acad Sci 698:186-192, 1994
68. Silvestrini R, Daidone MG, Mastore M, Di Fronzo G, Coradini D, Boracchi P, Squicciarini P, Salvadori B, Veronesi U: Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy. J Clin Oncol 11:1150-1155, 1993
69. Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P, Salvadori B: P53 and Bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14:1604-1610, 1996
70. Paradiso A, Mangia A, Barletta A, Catino AM, Giannuzzi A, Schittulli F, Radogna N, Longo S, Palmieri D, Marzullo F, et al: Randomized clinical trial of adjuvant chemotherapy in patients with node negative, fast proliferating breast cancer. Drugs 45 (Suppl 2):68-74, 1983